“With our disruptive EYEMATE system, we are at the forefront of modern glaucoma care by combining proprietary sensing technology with IoT and analytics backed digital health solutions. The EYEMATE system enables ophthalmologists to provide better care to their patients,” says Max G. Ostermeier, CEO of Implandata.
Through years of extensive R&D, the company has mastered the art of developing miniaturized implants capable of non-invasively detecting ‘subtle pressure variations’ on one of the most sensitive human organs. Implandata thus fosters a massive leap of advancement in the world of teleophthalmology.
Glaucoma, wherein elevated IOP causes irreversible vision loss by permanently damaging the optic nerve, can only be kept on check by reducing and controlling IOP levels. Although there are numerous therapeutic options to control IOP, patients respond differently to them and a therapy response can quickly change over time. Current methods to measure IOP only allow infrequent in-office measurements and do not provide any information about habitual IOP or even IOP monitoring.The constant threat to lose vision or go blind, because of glaucoma, puts a lot of emotional burden on patients and their families; this is further aggravated by the fact that patients have very limited information about their IOP. Glaucoma is also called the ‘silent thief of sight’ as elevated IOP causing vision loss is typically asymptomatic.
Implandata’s EYEMATE system provides IOP data under normal life conditions at a previously unattainable quality and quantity and provides actionable information via digital solutions to an ophthalmologist.
We are at the forefront of modern glaucoma care by combining proprietary sensing technology with IoT and analytics backed digital health solutions
EYEMATE’s implant, which sizes up to less than the diameter of a ten-cent coin, can be easily implanted without any intervention of the patient’s daily routines. By accessing the implant’s data on EYEMATE’s cloud platform, eye doctors remain informed about their patient’s therapy progress which allows them to proactively titrate and optimize their therapy. Furthermore, with the options to self-monitor their data through a smart-phone app, the patients are also motivated to be involved and adhere to their therapy. “We are extremely pleased that all the patients who have attained our product so far are very satisfied and happy with it. We have not had any reports of safety issues with our product. All our devices are working properly for years and providing useful information, which is really important for a product targeting chronically ill patients,” says Ostermeier with pride.
Evidently, EYEMATE’s immense value proposition has received great appreciation from the medical community. The company has support and considerable investment from eye doctors. Also, several patients and patient organizations have backed the company at multiple levels.
Implandata is currently rolling out its EYEMATE system to ophthalmologists in Germany, Switzerland, and Austria, and will expand further into European countries in 2019. From 2020 onwards, the company plans to start market activities in certain Asian regions, keeping an eye on the Chinese market. They are also preparing a first US IDE study, forecasting an FDA PMA approval in a few years.